Table 1.
Characteristics of the Included Studies
| Reference | Country | Study Design | Intervention with Avanafil | Samples (n) | Age (Mean ± SD) or Median (IQR) | ED Severity, Mild/Moderate/Severe | Mean ED Duration, Months | Treatment Duration | Inclusion Population |
|---|---|---|---|---|---|---|---|---|---|
| Belkoff et al, 201316 | USA | RCT, open label | A 100mg A 100/200mg |
171 536 |
54.2 ± 10.9 57.1 ± 9.9 |
64/59/48 142/177/217 |
63.7 ± 58.6 79.8 ± 72.3 |
52 weeks | Men ≥18 years, diabetic or non-diabetic, ≥6-month history of mild to severe ED |
| Elkamshoushi et al, 202117 | Egypt | RCT, double blind | A 50mg Placebo |
70 70 |
59.3 ± 6.5 61.6 ± 5.5 |
32/18/20 NR |
NR | 4 weeks | Men ≥18 years, ≥12-month history of mild to severe ED |
| Goldsteina et al, 201218 | USA | RCT, double blind | A 50mg A 100mg A 200mg Placebo |
154 157 156 155 |
55.5 56.4 56.1 55.8 |
55/48/51 54/51/52 53/52/51 55/49/51 |
79.5 88.5 68.4 75.4 |
12 weeks | Men ≥18 years, ≥6-month history of mild to severe ED |
| Goldsteinb et al, 201219 | USA | RCT, double blind | A 100mg A 200mg Placebo |
129 131 130 |
58.2 ± 9.6 57.5 ± 9.0 58.2 ± 8.6 |
28/40/61 28/42/61 29/40/61 |
73.8 ± 53.1 64.6 ± 44.7 78.7 ± 66.6 |
12 weeks | Men ≥18 years, type 1 or 2 diabetes, ≥6-month history of mild to severe ED |
| Hellstrom et al, 201220 | USA | RCT, Single blind | A 50mg A 100mg A 200mg |
26 28 28 |
52.1 ± 9.4 53.2 ± 10.3 49.3 ± 9.7 |
2/24/0 6/22/0 6/22/0 |
66.8 ± 75.4 62.3 ± 74.4 45.7 ± 42.3 |
52 weeks | Men aged 35–70 years, ≥6-month history of mild to moderate ED |
| Hellstrom et al, 201521 | USA | RCT, double blind | A 100mg A 200mg Placebo |
147 148 145 |
58.5 ± 10.2 57.9 ± 10.6 58.3 ± 9.9 |
36/49/62 37/51/60 39/46/60 |
81.0 ± 58.17 95.6 ± 86.31 88.8 ± 61.98 |
12 weeks | Men ≥18 years, diabetic or non-diabetic, ≥6-month history of mild to severe ED |
| Jiang et al, 202122 | China | RCT, double blind | A 100mg A 200mg Placebo |
64 69 65 |
40.0 ± 11.3 39.0 ± 11.0 40.5 ± 10.9 |
32/23/14 32/22/10 29/25/11 |
26.8 ± 32.1 28.5 ± 45.7 33.9 ± 38.3 |
12 weeks | Men aged 22–65 years, ≥3-month history of ED |
| Kumar et al, 202223 | India | RCT, double blind | A 100mg/200mg S 50mg/100mg |
110 107 |
36.4 ± 9.0 37.1 ± 8.9 |
16/64/30 8/68/31 |
8.6 ± 5.6 7.9 ± 4.4 |
12 weeks | Men ≥21 years, ≥3-month history of ED |
| Mulhall et al, 201324 | USA | RCT, double blind | A 100mg A 200mg Placebo |
99 99 100 |
58.9 ± 5.88 57.7 ± 6.6 58.6 ± 5.87 |
7/17/75 12/19/68 8/22/70 |
NR | 12 weeks | Men aged 18–70 years, ≥6-month history of ED, after nerve-sparing radical prostatectomy |
| Park et al, 201725 | Korea | RCT, double blind | A 50mg A 100mg A 200mg Placebo |
40 40 39 39 |
55.7 ± 7.6 57.2 ± 8.0 56.1 ± 6.7 56.7 ± 9.0 |
NR | 57.6 ± 48.0 62.4 ± 60.0 55.2 ± 40.8 70.8 ± 56.4 |
8 weeks | Men aged 19–70 years, ≥6-month history of ED |
| Zhao et al, 201227 | Korea | RCT, double blind | Avanafil 100mg Avanafil 200mg Placebo |
68 66 66 |
55.8 ± 8.2 56.6 ± 0.3 54.9 ± 8.9 |
23/34/11 22/28/16 19/34/13 |
NR | 12 weeks | Men >20 years, ≥6-month history of ED |
Abbreviations: RCT, randomized controlled trial; A, vanafil; S, sildenafil; SD, standard deviation; IQR, interquartile range; ED, erectile dysfunction; NR, not reported.